
BF Biosciences IPO’s book building phase will be held on 25th and 26th September where high net worth individuals and institutional investors will subscribe to 100 per cent of the issue size.
BF Biosciences, a leader in the biotech pharmaceuticals sector in Pakistan, is set to raise between Rs1.38 and Rs1.93 billion to expand its key product lines and obtain export certifications.
The floor price for the issue has been set at Rs55 per share through a 100 percent book building process.
The unsubscribed shares, if any, of the general subscription portion would be allocated to the successful bidders of the book building portion on a pro-rata basis. The issuer will utilize any additional funds raised above the floor price in managing its additional requirements for capex and working capital needs.
BF Biosciences has estimated that the maximum strike price for the IPO may climb to Rs77 per share that would increase the funds raised to Rs1.93 billion.
This strategic initiative is expected to drive significant growth in both the company’s top line and profitability as company has already completed a brownfield expansion and IPO will also help the company to manage working capital needs of the aforesaid expansion.
Arif Habib Limited has been appointed as a lead manager and book runner to the issue.
In the gripping saga of Nancy Guthrie’s abduction from Arizona, local law enforcement remains in…
Field Marshal Syed Asim Munir, Chief of Army Staff and Chief of Defence Forces, emphasized…
Minions Take Center Stage in Milan: A Figure Skater's Triumph Over Music Rights The 2026…
In Karachi, Sindh Governor Announces Single-Member Inquiry Commission to Investigate Gul Plaza Tragedy Following a…
In 1993, during an ambitious skiing trip in Austria, Princess Diana’s former bodyguard, Ken Wharfe,…
The United Arab Emirates (UAE) Ambassador Hammad Obaid Ibrahim Salem Al-Zaabi recently highlighted significant progress…
This website uses cookies.